Supernus Pharmaceuticals, Inc. $SUPN Shares Acquired by Systematic Financial Management LP

Systematic Financial Management LP lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 4.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 304,226 shares of the specialty pharmaceutical company’s stock after acquiring an additional 11,966 shares during the quarter. Systematic Financial Management LP’s holdings in Supernus Pharmaceuticals were worth $15,120,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. EverSource Wealth Advisors LLC increased its holdings in shares of Supernus Pharmaceuticals by 242.4% during the 4th quarter. EverSource Wealth Advisors LLC now owns 4,852 shares of the specialty pharmaceutical company’s stock worth $241,000 after buying an additional 3,435 shares during the last quarter. Global Retirement Partners LLC increased its holdings in shares of Supernus Pharmaceuticals by 532.4% during the 4th quarter. Global Retirement Partners LLC now owns 1,404 shares of the specialty pharmaceutical company’s stock worth $70,000 after buying an additional 1,182 shares during the last quarter. PSP Research LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $535,000. Covestor Ltd increased its holdings in shares of Supernus Pharmaceuticals by 16.2% during the 4th quarter. Covestor Ltd now owns 2,683 shares of the specialty pharmaceutical company’s stock worth $133,000 after buying an additional 374 shares during the last quarter. Finally, ProShare Advisors LLC increased its holdings in shares of Supernus Pharmaceuticals by 7.1% during the 4th quarter. ProShare Advisors LLC now owns 13,064 shares of the specialty pharmaceutical company’s stock worth $649,000 after buying an additional 866 shares during the last quarter.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $48.21 on Monday. The stock has a market cap of $2.80 billion, a P/E ratio of -94.53, a price-to-earnings-growth ratio of 1.04 and a beta of 0.57. The company has a fifty day simple moving average of $49.99 and a 200-day simple moving average of $49.64. Supernus Pharmaceuticals, Inc. has a 12-month low of $30.83 and a 12-month high of $59.68.

Analysts Set New Price Targets

SUPN has been the subject of a number of recent analyst reports. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Finally, Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $62.17.

Insider Activity

In other news, VP Padmanabh P. Bhatt sold 7,250 shares of Supernus Pharmaceuticals stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $49.60, for a total transaction of $359,600.00. Following the completion of the sale, the vice president directly owned 17,044 shares of the company’s stock, valued at approximately $845,382.40. The trade was a 29.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Frederick M. Hudson sold 5,369 shares of the business’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $50.61, for a total transaction of $271,725.09. Following the completion of the sale, the director directly owned 60,413 shares of the company’s stock, valued at approximately $3,057,501.93. This trade represents a 8.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 116,406 shares of company stock valued at $5,911,086 in the last 90 days. Company insiders own 8.80% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.